Alterity Financial Statements From 2010 to 2024

ATHE Stock  USD 1.91  0.04  2.05%   
Alterity Therapeutics financial statements provide useful quarterly and yearly information to potential Alterity Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Alterity Therapeutics financial statements helps investors assess Alterity Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alterity Therapeutics' valuation are summarized below:
Gross Profit
3.6 M
Market Capitalization
17.4 M
Enterprise Value Revenue
113.9898
Revenue
3.4 M
Earnings Share
(1.81)
There are over one hundred nineteen available fundamental signals for Alterity Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Alterity Therapeutics' prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 9.7 B. The current year's Enterprise Value is expected to grow to about 9.7 B

Alterity Therapeutics Total Revenue

3.15 Million

Check Alterity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alterity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.9 K, Other Operating Expenses of 9.7 M or Total Operating Expenses of 9.7 M, as well as many indicators such as Price To Sales Ratio of 3.7 K, Dividend Yield of 0.0 or PTB Ratio of 424. Alterity financial statements analysis is a perfect complement when working with Alterity Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Alterity Therapeutics Correlation against competitors.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

Alterity Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets21.8 M31.4 M25 M
Slightly volatile
Cash15.8 M18.1 M19.3 M
Pretty Stable
Cash And Short Term Investments15.8 M18.1 M19.3 M
Pretty Stable
Common Stock Shares Outstanding2.9 B2.8 B704.5 M
Slightly volatile
Liabilities And Stockholders Equity21.8 M31.4 M25 M
Slightly volatile
Total Current Assets18.6 M31.1 M24.6 M
Slightly volatile
Common Stock258.4 M246.1 M157 M
Slightly volatile
Total Current Liabilities2.7 MM3.1 M
Slightly volatile
Property Plant And Equipment Net324.7 K309.2 K118.8 K
Slightly volatile
Accounts Payable1.3 MM1.2 M
Slightly volatile
Non Current Assets Total229.9 K242 KM
Slightly volatile
Net Receivables10.5 M10 M5.1 M
Slightly volatile
Other Current Assets34 K35.8 K47.2 K
Slightly volatile
Total Liabilities2.8 M5.2 M3.1 M
Slightly volatile
Common Stock Total Equity128.1 M227.1 M147.1 M
Slightly volatile
Non Current Liabilities Total69.6 K110.4 K34.5 K
Slightly volatile
Property Plant And Equipment Gross880 K838.1 K256.8 K
Slightly volatile
Current Deferred Revenue3.7 M3.6 M1.3 M
Slightly volatile
Other Liabilities15 K22.4 K11 K
Slightly volatile
Net Tangible Assets24.6 M26.2 M21.6 M
Slightly volatile
Property Plant Equipment324.7 K309.2 K112.6 K
Slightly volatile
Net Invested Capital23.9 M26.2 M23 M
Very volatile
Net Working Capital23.8 M26.1 M22.9 M
Very volatile
Capital Stock207.4 M246.1 M176.6 M
Slightly volatile

Alterity Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses9.7 M16.5 M10.5 M
Slightly volatile
Total Revenue3.1 MM1.2 M
Slightly volatile
Research Development7.7 M15.2 M9.9 M
Slightly volatile
Depreciation And Amortization87.4 K92 K123.8 K
Slightly volatile
Selling General Administrative3.5 M4.4 MM
Slightly volatile
Selling And Marketing Expenses119.9 K83.9 K120.7 K
Slightly volatile
Cost Of Revenue87.4 K92 K226 K
Slightly volatile
Interest Income14.1 K14.8 K1.7 M
Slightly volatile
Net Interest Income14.1 K14.8 K88.1 K
Slightly volatile
Reconciled Depreciation65.5 K117.6 K48.5 K
Slightly volatile

Alterity Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow42 M40 M22.5 M
Slightly volatile
Depreciation87.4 K92 K125.2 K
Slightly volatile
Capital Expenditures4.3 K4.5 K27.1 K
Slightly volatile
End Period Cash Flow18.1 M18.1 M19.7 M
Pretty Stable
Issuance Of Capital Stock265.9 K279.9 K12 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.7 K3.5 K1.2 K
Slightly volatile
Days Sales OutstandingK1.1 K5.5 K
Slightly volatile
Invested Capital0.01010.01060.014
Slightly volatile
Average Payables2.1 MM1.4 M
Slightly volatile
Stock Based Compensation To Revenue0.40.431.9005
Slightly volatile
Payables Turnover0.06510.06850.5335
Slightly volatile
Sales General And Administrative To Revenue2.072.1812.9479
Slightly volatile
Research And Ddevelopement To Revenue4.334.5533.3857
Slightly volatile
Cash Per Share0.00710.007515.2823
Slightly volatile
Capex To Operating Cash Flow3.0E-43.0E-40.0039
Slightly volatile
Days Payables Outstanding5.8 K5.5 K2.4 K
Slightly volatile
Income Quality0.761.311.0718
Very volatile
Intangibles To Total Assets0.30.320.3152
Slightly volatile
Net Debt To EBITDA1.751.181.7623
Very volatile
Current Ratio6.365.568.2565
Pretty Stable
Tangible Book Value Per Share0.01030.010816.8111
Slightly volatile
Receivables Turnover0.330.350.691
Slightly volatile
Graham Number0.03790.039948.4851
Slightly volatile
Debt To Equity0.01010.01060.014
Slightly volatile
Graham Net Net0.00860.00915.6744
Slightly volatile
Average Receivables6.3 MM4.3 M
Slightly volatile
Revenue Per Share0.00120.00120.325
Slightly volatile
Interest Debt Per Share1.0E-41.0E-40.2002
Slightly volatile
Debt To Assets0.00840.00890.0111
Slightly volatile
Operating Cycle5.9 K9.3 K7.5 K
Very volatile
Days Of Payables Outstanding5.8 K5.5 K2.4 K
Slightly volatile
Ebt Per Ebit1.211.031.0714
Slightly volatile
Long Term Debt To Capitalization0.00430.00410.0011
Slightly volatile
Total Debt To Capitalization0.010.01050.0135
Slightly volatile
Debt Equity Ratio0.01010.01060.014
Slightly volatile
Quick Ratio6.215.028.0603
Pretty Stable
Dividend Paid And Capex Coverage Ratio119125934
Very volatile
Net Income Per E B T0.80.910.9852
Slightly volatile
Cash Ratio5.53.246.6586
Pretty Stable
Days Of Sales OutstandingK1.1 K5.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0212
Slightly volatile
Fixed Asset Turnover6.778.738.094
Slightly volatile
Capital Expenditure Coverage Ratio119125934
Very volatile
Debt Ratio0.00840.00890.0111
Slightly volatile
Price Sales Ratio3.7 K3.5 K1.2 K
Slightly volatile
Asset Turnover0.120.110.041
Slightly volatile

Alterity Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.7 B9.2 B3.9 B
Slightly volatile

Alterity Fundamental Market Drivers

Cash And Short Term Investments15.8 M

About Alterity Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Alterity Therapeutics income statement, its balance sheet, and the statement of cash flows. Alterity Therapeutics investors use historical funamental indicators, such as Alterity Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Alterity Therapeutics investors may use each financial statement separately, they are all related. The changes in Alterity Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alterity Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alterity Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alterity Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M3.7 M
Total RevenueM3.1 M
Cost Of Revenue92 K87.4 K
Stock Based Compensation To Revenue 0.43  0.40 
Sales General And Administrative To Revenue 2.18  2.07 
Research And Ddevelopement To Revenue 4.55  4.33 
Capex To Revenue(0)(0)
Revenue Per Share 0  0 
Ebit Per Revenue(6.74)(7.08)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Alterity Stock

When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:
Check out the analysis of Alterity Therapeutics Correlation against competitors.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.81)
Revenue Per Share
0.6
Quarterly Revenue Growth
(0.20)
Return On Assets
(0.29)
Return On Equity
(0.54)
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.